Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I3RD
|
|||
| Former ID |
DNCL002184
|
|||
| Drug Name |
TAK-733
|
|||
| Synonyms |
TAK-733; 1035555-63-5; TAK733; TAK 733; UNII-5J61HSP0QJ; (R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione; 5J61HSP0QJ; CHEMBL1615025; 3-[(2r)-2,3-Dihydroxypropyl]-6-Fluoro-5-[(2-Fluoro-4-Iodophenyl)amino]-8-Methylpyrido[2,3-D]pyrimidine-4,7(3h,8h)-Dione; MLS006011054; SCHEMBL1528606; GTPL9911; DTXSID20648089; MolPort-023-293-497; RCLQNICOARASSR-SECBINFHSA-N; example 18 [US8470837]; AOB87182; EX-A2164; BCP06625
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Millennium Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H15F2IN4O4
|
|||
| Canonical SMILES |
CN1C2=C(C(=C(C1=O)F)NC3=C(C=C(C=C3)I)F)C(=O)N(C=N2)CC(CO)O
|
|||
| InChI |
1S/C17H15F2IN4O4/c1-23-15-12(16(27)24(7-21-15)5-9(26)6-25)14(13(19)17(23)28)22-11-3-2-8(20)4-10(11)18/h2-4,7,9,22,25-26H,5-6H2,1H3/t9-/m1/s1
|
|||
| InChIKey |
RCLQNICOARASSR-SECBINFHSA-N
|
|||
| CAS Number |
CAS 1035555-63-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00948467) Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.